Literature DB >> 33100054

Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee.

Merrill D Benson1, Joel N Buxbaum2, David S Eisenberg3, Giampaolo Merlini4, Maria J M Saraiva5, Yoshiki Sekijima6, Jean D Sipe7, Per Westermark8.   

Abstract

The ISA Nomenclature Committee met electronically before and directly after the XVII ISA International Symposium on Amyloidosis, which, unfortunately, had to be virtual in September 2020 due to the ongoing COVID-19 pandemic instead of a planned meeting in Tarragona in March. In addition to confirmation of basic nomenclature, several additional concepts were discussed, which are used in scientific amyloid literature. Among such concepts are cytotoxic oligomers, protofibrils, primary and secondary nucleation, seeding and cross-seeding, amyloid signature proteins, and amyloid plaques. Recommendations for their use are given. Definitions of amyloid and amyloidosis are confirmed. Possible novel human amyloid fibril proteins, appearing as 'classical' in vivo amyloid, were discussed. It was decided to include fibulin-like extracellular matrix protein 1 (amyloid protein: AEFEMP1), which appears as localised amyloid in portal veins. There are several possible amyloid proteins under investigation, and these are included in a new Table.

Entities:  

Keywords:  Amyloid; aggegation; fibril protein; inclusion; nomenclature; oligomer

Mesh:

Substances:

Year:  2020        PMID: 33100054     DOI: 10.1080/13506129.2020.1835263

Source DB:  PubMed          Journal:  Amyloid        ISSN: 1350-6129            Impact factor:   7.141


  56 in total

1.  Coronary microvascular disease in hypertrophic and infiltrative cardiomyopathies.

Authors:  Andreas A Giannopoulos; Ronny R Buechel; Philipp A Kaufmann
Journal:  J Nucl Cardiol       Date:  2022-08-01       Impact factor: 3.872

2.  Bystander LECT2 amyloidosis in tumor nephrectomy.

Authors:  A J Gallan; B Bhasin-Chhabra; D Kilari; S Johnson; A D'Souza
Journal:  CEN Case Rep       Date:  2022-08-20

Review 3.  Deciphering the Structure and Formation of Amyloids in Neurodegenerative Diseases With Chemical Biology Tools.

Authors:  Isabelle Landrieu; Elian Dupré; Davy Sinnaeve; Léa El Hajjar; Caroline Smet-Nocca
Journal:  Front Chem       Date:  2022-05-12       Impact factor: 5.545

4.  Pathway Dependence of the Formation and Development of Prefibrillar Aggregates in Insulin B Chain.

Authors:  Yuki Yoshikawa; Keisuke Yuzu; Naoki Yamamoto; Ken Morishima; Rintaro Inoue; Masaaki Sugiyama; Tetsushi Iwasaki; Masatomo So; Yuji Goto; Atsuo Tamura; Eri Chatani
Journal:  Molecules       Date:  2022-06-21       Impact factor: 4.927

5.  Cell-to-cell transmission of p53 aggregates: a novel player in oncology?

Authors:  Naoyuki Iwahashi; Midori Ikezaki; Hiroyuki Saito; Kenji Uchimura; Kazuchika Nishitsuji
Journal:  Mol Cell Oncol       Date:  2021-03-22

Review 6.  Multidisciplinary Approaches for Transthyretin Amyloidosis.

Authors:  Haruki Koike; Takahiro Okumura; Toyoaki Murohara; Masahisa Katsuno
Journal:  Cardiol Ther       Date:  2021-06-04

7.  Species-barrier on the cross-species oral transmission of bovine AA amyloidosis in mice.

Authors:  Susumu Iwaide; Naoki Ujike; Kyoko Kobayashi; Yukiko Sassa; Tomoaki Murakami
Journal:  J Vet Med Sci       Date:  2021-04-28       Impact factor: 1.267

8.  Autopsy findings in a patient with primary systemic AL (kappa light chain) amyloidosis.

Authors:  Felipe Lourenço Ledesma; Jussara Bianchi Castelli
Journal:  Autops Case Rep       Date:  2021-05-06

Review 9.  Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis.

Authors:  Antonia Carroll; P James Dyck; Mamede de Carvalho; Marina Kennerson; Mary M Reilly; Matthew C Kiernan; Steve Vucic
Journal:  J Neurol Neurosurg Psychiatry       Date:  2022-03-07       Impact factor: 13.654

10.  Protein Amyloid Cofactors: Charged Side-Chain Arrays Meet Their Match?

Authors:  Emily Lewkowicz; Shobini Jayaraman; Olga Gursky
Journal:  Trends Biochem Sci       Date:  2021-06-28       Impact factor: 13.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.